PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ: MDCO) today announced its financial results for the fourth quarter and full year 2006. Full year 2006 revenue of $214 million exceeded the upper end of the Company’s guidance of $205 to $212 million. The Company reported fully diluted earnings per share for the year of $1.25, including a tax benefit provided for by FAS 109 under U.S. generally accepted accounting principles (GAAP). Excluding this tax benefit, the Company had non-GAAP earnings per share of $0.34, exceeding the Company’s forecasted range of $0.28 to $0.32 per share.
